Correction to: Alpha-1 Antitrypsin Deficiency: a Rare Disease?

Roxana Cortes-Lopez¹ · Igor Barjaktarevic¹

Published online: 12 September 2020

© Springer Science+Business Media, LLC, part of Springer Nature 2020

Correction to: Current Allergy Asthma Reports (2020) 20:51

<https://doi.org/10.1007/s11882-020-00942-4>

The original version of this article contained errors in Table 3 on page 6. In the last row, Trypsone was listed as a Grifols product in EU. This product has been discontinued.

The corrected table is presented in this erratum.

Table 3 Available augmentation replacement therapies for alpha-1 antitrypsin deficiency

Product	Manufacturer	Country	Formulation	Dose	Dosing interval	Concentration after reconstitution	Rate of infusion	Duration of infusion
Prolastin C	Grifols	USA	Lyophilized	60 mg/Kg	Weekly	50 mg/mL	0.08 ml/kg/min	15 min
Prolastin C Liquid	Grifols	USA	Liquid	60 mg/Kg	Weekly	50 mg/mL	0.08 ml/kg/min	15 min
Glassia	Takeda/Kamada	USA/Israel	Liquid	60 mg/Kg	Weekly	20 mg/mL	0.04 mL/kg/min	60–80 min
Aralast	Takeda	USA	Lyophilized	60 mg/Kg	Weekly	20 mg/mL	0.08 ml/kg/min	40 min
Zemaira	CSL Behring	USA	Lyophilized	60 mg/Kg	Weekly	50 mg/mL	0.08 ml/kg/min	15 min
Alfalastin	Laboratoire français fractionnement et de Biotechnologies	France	Lyophilized	60 mg/Kg	Weekly	50 mg/mL	4 ml/mn	15 min
Respreeza	CSL Behring	EU	Lyophilized	60 mg/Kg	Weekly	50 mg/mL	0.08 ml/kg/min	15 min
Prolastin/Prolastina	Grifols	EU	Lyophilized	60 mg/Kg	Weekly	25 mg/mL	0.08 ml/kg/min	30 min

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The online version of the original article can be found at <https://doi.org/10.1007/s11882-020-00942-4>

✉ Igor Barjaktarevic
ibarjaktarevic@mednet.ucla.edu

¹ Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine at UCLA, 10833 Le Conte Avenue, CHS, Los Angeles, CA 90095, USA